Drug intelligence / Profile preview

tetanus and diphtheria toxoids (IP Biotech)

Development stage
Unknown
Lead developer
IP Biotech
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

IP Biotech's Tetanus-Diphtheria (Td) vaccine is a bivalent inactivated vaccine designed to provide active immunity against tetanus and diphtheria. It is primarily utilized as a booster dose for adolescents and adults to maintain protective antibody levels. The vaccine formulation consists of purified tetanus and diphtheria toxoids—toxins that have been chemically modified to eliminate toxicity while preserving their ability to elicit an immune response. Upon administration, the host's immune system recognizes these toxoids and produces specific antitoxins. These antibodies are capable of neutralizing the potent exotoxins produced by Clostridium tetani and Corynebacterium diphtheriae during infection, thereby preventing the severe clinical complications associated with these pathogens, such as muscle spasms and respiratory obstruction.

Brand names
Tetanus-Diphtheria Vaccine
Other names
Td vaccineTetanus-Diphtheria vaccine
02

Targets

Diphtheria toxin

Beyond the preview

Go deeper on tetanus and diphtheria toxoids (IP Biotech).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tetanus and diphtheria toxoids (IP Biotech).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call